

Innovative Medicines Initiative (IMI) and other Public Private Partnerships: Educational Ambitions

Oslo EAFP

19 June 2009







1200 km









IMI Public and Private Founders and Funders











MERCK SHARP & DOHME < Roche



















Boehringer Ingelheim

AstraZeneca





























The Research Focus of IMI



The Four Pillars of IMI Research Agenda



IMI JU First call Topics with projects in negotiation

- 2 Non-genotoxic Carcinogenesis
- 3 Expert Systems for in silico Toxicity Prediction
- 5 Qualification of Translational Safety Biomarkers
- 6 Strengthening the Monitoring of Benefit/Risk
- 7 Islet Cell Research
- 8 Surrogate Markers for Vascular Endpoints
- 9 Pain Research
- 10 New Tools for the Development of Novel Therapies in Psychiatric Disorders
- 11 Neurodegenerative Disorders
- 12 Understanding Severe Asthma
- 13 COPD Patient Reported Outcomes
- 14 European Medicines Research Training Network
- 15 Safety Sciences for Medicines Training Programme
- 16 Pharmaceutical Medicine Training Programme
- 18 Pharmacovigilance Training Programme







IMI 1st round selected projects & expected outcomes...#3

12. European Medicines Research Training Network

Expected outcome: a European biopharmaceutical research training platform providing a sustainable academia-industry cross-disciplinary approach to efficient organisation of training courses on emerging science and technologies across Europe

13. Safety sciences for medicines training programme

Expected outcome: training programme integrating all safety-relevant disciplines linking animal and human/patient safety data thereby facilitating a more holistic evaluation of new medicines

14. Pharmaceutical medicine training programme

Expected outcome: establish a network of academic centres that delivers postgraduate training programmes in pharmaceutical medicine including quality management of the processes and outcomes

15. Pharmacovigilance training programme

Expected outcome: customised training programmes for professionals in pharmacovigilance from industry and regulatory agencies to support proactive pharmacovigilance and risk management of medicines





Dutch Top Institute Pharma: TI Pharma





Lisbon Strategy



In March 2000, the European Council in Lisbon set out a ten-year strategy to make the Union "the most competitive and dynamic knowledge-based economy in the world, capable of sustainable economic growth with more and better jobs and greater social cohesion". During the Swedish Presidency, in



European Research & Development investment to 3% of the European Union's Gross Domestic Product

Conquistadores-monument; the explorers....




GDP spent on Research & Development (2004)

Country	percentage of GDP	fraction industry (%)
Netherlands	1.78 %	51
Finland	3.46 %	70
Sweden	3.86 %	65
Denmark	2.48 %	60
Germany	2.50 %	67
France	2.14 %	52
Japan	3.18 %	75
China	1.23 %	66
USA	2.68 %	64

Lisbon agenda...... 3%




The Netherlands has work to do to realize a 'knowledge economy' cf. Lisbon Agenda, 2000





Publication scores knowledge economies

Publication scores scientific areas in the Netherlands



TI Pharma: a Public Private Partnership



Between ivory tower and smokestack.....



TI Pharma







Jointly shaping the future of medicines



23 academic and 38 industry partners form 44 multilateral publicprivate project consortia



- ▶ 23 academic participants
- ▶ 38 industrial participants
- ▶ Per project at least 3 partners, of which at least one academic, and one industrial
- Total: 45 multilateral consortia working on projects ranging in size from EUR 2 to 18 million (over 4-5 years)

Note: Agamyxis and Virosome Biologicals missing (no logo available)

250 million euros in 4 years



It's about Health and Wealth




Arend van Dam

1 minute elevator pitch



TI Pharma characteristics

- ▶ A public private partnership: a PPP
- ▶ 60 million euro/year for 4-6 years
- Consortia with (37) industry and (20) academia working on projects
- Pre-competitive research
- ▶ Translational in character of research
- ▶ A virtual institute





But above all: quality!




TI Pharma challenges in creating a new generation of researchers

- ▶ Teamwork
- ► Bridging academia and industry
- Multidisciplinary
- ▶ Spans the entire discovery/development/.... process













The current portfolio of 42 projects employs 541 persons / 413 FTE's

Workforce in persons and FTE's





PhD students and Post-Docs: gender is equally represented and foreigners account for 1/4 to 1/3





In 2009 the 'on top' program is extended with three new courses

New in 2009 'On top' program Postdoc PhD Business & Entrepreneurial Drug Discovery Simulation Skills **Intellectual property DDIS** BES Drug Discovery & Drug Development Simulation Development Cycle **Project Management DDES** DDC General education program **Industrial career opportunities** Ph.D. /post doc training programmes already available




EUFEPS/TI Pharma Catalogue

catalogue of available courses

http://www.etplatform.eu/database



Courses in biomedical/pharmaceutical sciences in Netherlands, Denmark, Sweden, Finland, part of Switzerland




EUFEPS Course Catalogue

Therapeutic Areas

Therapeutic Areas





Cardiovasculair Diseases

Cardiovasculair Diseases

Physiology of the heart

and circulation

cardiovascular

Introduction into

PhD students

PhD students

© TI Pharma 2006 | login | contact | disclaimer

CARIM

CARIM





EUFEPS Course Catalogue BETA

Home Database Explanation Criteria Submit a Course

Welcome to the EUFEPS Course Catalogue

Rapidly changing demands, created by emerging science and techniques in pharmaceutical research and development, call for top quality education and training.

To facilitate post-graduate researchers (PhD students, Post-docs and research professionals) in fulfilling their training needs, this website provides an overview of high quality training courses in (bio-)pharmaceutical sciences and related subjects throughout Europe.

Courses are categorized along four main categories (Therapeutic areas, Enabling Technologies, Methodology, and Auxiliary skills) which are divided in several sub-categories. Next to a search function, a filter option allows you to rapidly find the courses of your interest.

The EUFEPS Course Catalogue is currently building the database to create critical mass. In the next few months more countries and universities will be included.

Database

To browse or search through the database, click on the button below.

to database >

Submit a Course


Now you can submit a course to include it in the database.

submit a course >

Insyde web design



EUFEPS Course Catalogue BETA











Home Database Explanation Criteria Submit a Course

< Back to database

Epidemiology and Apllied Statistics

Δim

To learn about the concepts, principles, and methods in epidemiology. The participants will become familiar with study designs, methodological problems, statistical analyses and causal inference.

Location & Organization

Organizer

GUIDE - Graduate School for Drug Exploration, Groningen

Course Director

Prof. H.M. Boezen

Location / venue

Groningen

Timing & Workload

Duration Two weeks

ECTS points Three

Frequency Once a year

Teaching methods used

Lectures, assignments and practicals.

Examination yes

Criteria

Is the course taught in English? yes

Is documentation available? (book, syllabus)? yes

Is the course open for external researchers? yes

More Information

http://www.graduateschoolguide.nl/html/education/courses/epidemiologyandappliedstaistics.htm

Categories

Therapeutic Areas: None

Enabling Technologies: Epidemiology

Methodology: None Auxiliary skills: None

Target Group

All researchers

Country

NL

City


Groningen

More information

view website










Course Catalogue: www.tipharma.com





Basic information to be submitted per course (more information can be found on the linked website)

Basic information:

- ▶ Course title
- Main category
 - General skills
 - Methodology
 - Therapeutic areas
 - Enabling technologies)
- Sub category (to be defined, depending on outcome of inventory)
- ► Target group ('PhD students', 'Post-docs', 'PhD's and Post-docs' & 'Other')
- Aim / objective

Location & organization:

- Organizer
- Faculty (one of the criteria)
- ▶ Location / venue
- Country
- Costs

Timing & workload:

- Duration (one of the criteria)
- ► ECTS points (one of the criteria)
- ► Frequency (one of the criteria)
- ▶ Date of next course
- Methods used
- Examination (one of the criteria)

Criteria: (for selection, not for display on site)

- ▶ Is the course taught in English?
- Is documentation available? (book, syllabus)
- Is the course open for external researchers?
- What quality assurance system is in place?

Other:

- Remarks
- ▶ Deep link to site with more information
- Email address of submitter (needed to ask to keep information updated)



Courses are included in the inventory if they fulfill a set criteria; these criteria are judged upon by an expert panel (prototype available)

- ▶ Criteria to include courses in the EUFEPS training platform:
 - ▶ Yes or No criteria:
 - Taught in English
 - Run periodically (at least every two years)
 - ► ECTS points: at least 1 (=equivalent to 2-3 days)
 - Open for external researchers
 - Course is concluded with an exam
 - ► To be judged by expert panel:
 - ▶ High quality syllabus or documentation available
 - Clear learning objectives
 - Faculty composition
- An expert panel judges these criteria before a course is included in the inventory
- ► The expert panel consists of:
 - ▶ ... to be composed ... (in progress)



In 2009 the 'on top' program is extended with three new courses

'On top' program Postdoc PhD Business & Entrepreneurial Drug Discovery Simulation Skills **DDIS** BES Drug Discovery & Drug Development Simulation Development Cycle **DDES** DDC General education program Ph.D. /post doc training programmes already available

New in 2009

Intellectual property

Project Management

Industrial career opportunities

Drug Discovery Simulation

a simulation that covers the whole drug discovery process

General information

In this course the drug discovery process will be simulated, from the beginning to the end: from target and lead discovery through phases of lead optimization and preclinical safety tests. This TI Pharma course provides its researchers with an interactive experience demonstrating the required competencies of the various players in the drug discovery process.

Objectives

Participants will work to achieve the following goals:

- Understanding the discovery process
- Understanding the role played by various relevant disciplines
- Experiencing relevant interactions and interfaces
- Learning the consequences of specific decisions and actions taken
- Learning what actions should be taken when carrying out a "real" process
- Teamwork/networking
- Developing one's own set of learning objectives

Course duration

Five full day sessions, including evenings, over a single week (Monday morning through Friday afternoon 2 pm).

Participation

The course is targeted at TI Pharma post docs and other industry based researchers. The TI Pharma course 'Drug Discovery & Development Cycle' (DDC) is recommended as a starter.

TI Pharma will build the teams for each course, based on relevant industry background and certain participants' areas of study.

Location

De Ruwenberg Conference Centre, Sint-Michielsgestel (www.ruwenberg.nl)

- ▶ real life simulations
- ▶ 5 day courses
- ▶ working in teams
- ▶ deliverables

www.tipharma.com



Drug Development Simulation from lead optimization via proof of concept to marketing

General information

In this course the drug development process will be simulated, from the beginning to the end: from lead optimization through proof of concept phases and clinical studies, culminating in developing marketing strategies. This TI Pharma course provides its researchers with an interactive experience demonstrating the required competencies of the various players in the drug development process.

Objectives

Participants will work to achieve the following goals:

- Understanding the development process
- Understanding the role played by various relevant disciplines
- Experiencing relevant interactions and interfaces
- Learning the consequences of specific decisions and actions taken
- Learning what actions should be taken when carrying out a "real" process
- Teamwork/networking
- Developing one's own set of learning objectives

Course duration

Five full day sessions, including evenings, over a single week (Monday morning through Friday afternoon 2 pm).

Participation

Participation is compulsory for TI Pharma post docs. A basic understanding of the industry's drug development process is a prerequisite for this course.

TI Pharma will build the teams for each course, based on relevant industry background and certain participants' areas of study.



Drug Discovery/Development Simulations 'excellent' for Post Docs

Work within a team and be a part of a 'virtual' pharmaceutical company, in order to develop drugs for a certain therapeutic area and to put them onto the market.



"Very instructive and fun as well" Thomas van Es

Questions?



"I recommend it to other post docs"

Marieke Ruiter



"Eye opener! I hope you will experience the same... "

Olivier van Beekum



In 2009 the 'on top' program is extended with three new courses

'On top' program Postdoc PhD Business & Entrepreneurial Drug Discovery Simulation Skills **DDIS** BES Drug Discovery & Drug Development Simulation Development Cycle **DDES** DDC General education program Ph.D. /post doc training programmes already available

New in 2009

Intellectual property

Project Management

Industrial career opportunities

